Martin brings over 30 years of broad commercial experience in pharmaceuticals to Porton Biopharma. He has spent many years in integrative leadership roles at the interface between R&D and commercial disciplines, has led numerous successful product launches, and has deep medicine development and supply chain experience. Most recently, Martin was Senior Vice President of Rare Diseases at GlaxoSmithKline where he had a long career in senior commercial leadership positions in both pharma and vaccines. Under Martin’s leadership, GSK launched the first life-saving gene therapy for children, Strimvelis, and developed a pipeline of ex-vivo gene therapy medicines which were recently acquired by Orchard Therapeutics.
Martin has prior board membership experience at Orchard Therapeutics, Alliance for Regenerative Medicine, and currently serves as non-executive director of Freeline Therapeutics and Evox Therapeutics. Martin is a Biology graduate.